WE Life Sciences’ Post

We’re thrilled to announce a collaboration with the world-class team at ARTBIO that expands our pipeline of cancer therapies into #radiopharmaceuticals, a class of drugs we believe will make an extraordinary impact on patient outcomes. Along with ARTBIO we will be co-creating and co-commercializing Helicon-enabled alpha-particle radioligand therapies, drawing on the unique strengths of each of our platforms to produce a new category of targeted radioligand therapy. We believe the combination could produce the best radiopharmaceutical platform that exists in our industry today: On the one side, ARTBIO is uniquely able to accomplish distributed manufacturing of lead-212 (²¹²Pb), one of the most promising isotopes for radiopharmaceutical use but that is challenging to utilize because of its short half-life. On the other side, Fog’s Helicon platform could be a best-in-class carrier of radiopharmaceuticals because of our ability to precisely tune our peptides to control tissue distribution and half-life. The general hyper-tunability of Helicons opens new possibilities both for intracellular targeting — where Fog’s wholly-owned pipeline is focused — as well as for extracellular delivery. At the intersection of these two unmatched platforms, there’s huge potential to create therapies that improve, extend and save the lives of people with cancer. Learn more in our press release: https://bwnews.pr/3wBXF7L #radioligandtherapy #cancer #oncology #peptides #Helicons #radiopharmaceutical #patients

✨ I'm thrilled to share that the US FDA has granted approval to Pfizer's groundbreaking treatment - Encorafenib and Binimetinib for BRAF V600E mutant metastatic non-small cell lung cancer (NSCLC). This marks a significant milestone in our quest to combat cancer and improve patient outcomes. These innovative therapies hold great promise for patients with this specific genetic mutation, offering new hope in the fight against NSCLC. Encorafenib and Binimetinib are designed to target the unique characteristics of this cancer type, demonstrating the power of precision medicine in our ongoing battle against this devastating disease. This achievement underscores the tireless efforts of scientists, researchers, and healthcare professionals dedicated to advancing cancer care. The journey from laboratory discovery to FDA approval is a testament to the power of collaboration and perseverance in the world of pharmaceuticals. Kudos to Pfizer and all those involved in bringing this life-changing therapy to fruition! As we celebrate this milestone, let's also reflect on the profound impact that such innovations have on the lives of patients and their families. Encorafenib and Binimetinib offer renewed hope, extending and improving the quality of life for those affected by NSCLC. #CancerResearch #InnovationInmedicine #USFDAApproval #Pfizer #NSCLC #MedicalBreakthroughs #PrecisionMedicine #healthcare

We are excited to announce that GlycoMantra will be attending the #BIO2024 conference in San Diego this week! We are looking forward to connecting with investors and strategic biotech/pharma partners to support our IND submission and initiation of Phase 1a/1b clinical trials of our lead drug candidate, GM101, in metastatic castration-resistant prostate cancer (mCRPC) patients who have developed resistance to hormone/androgen deprivation/androgen receptor inhibitor therapy. At BIO 2024, we are thrilled to share our progress in developing first-in-class carbohydrate-based biologics for treating resistant solid tumors including prostate cancer, as well as metabolic diseases such as Type-2 diabetes and lung and liver fibrosis/NASH. Our efforts have been bolstered by over $6.0M in non-dilutive funding from The National Institutes of Health/National Cancer Institute (NCI), which has allowed us to de-risk our technology and generate promising pre-clinical results, including in human mCRPC in humanized patient-derived xenograft (PDX) animal models. We look forward to meeting you at BIO 2024 - click below to send us a meeting request in the BIO partnering system! https://lnkd.in/er-CaxxF #BIO2024 #GlycoMantra #Oncology #Biotech #Pharma #ProstateCancer #Type2Diabetes #LiverFibrosis #NASH

💥 Super proud of our participating company OncoDNA, a $30 million project to fight cancer! 👊   🧬 The aim: to develop therapeutic cancer vaccines based on messenger RNA, products that are currently under development. And yes, the secret was well kept!   OncoDNA was selected by the European Commission from a list of 14 projects from five countries to support innovation in the pharmaceutical sector. This selection entitles the project to public investment of €30 million. A family of patents for these treatments has already been filed.   🚀 For our participating company, this represents a paradigm shift, since it's no longer just a question of carrying out biomarker tests to find the right treatment. The team of Jean-Pol Detiffe and Christophe Van Huffel is changing dimension and aims to become a producer of treatments that can all be customised in just a few days. A revolution! We're proud to be part of it!   Read in L'Echo article on OncoDNA's paradigm shift (link in commentary to this post) 👇   #lifesciences #cancer #health #treatment Gery Lefebvre Anne VEREECKE

✨ 𝗣𝗳𝗶𝘇𝗲𝗿 𝗘𝘅𝗽𝗮𝗻𝗱𝘀 𝗖𝗮𝗻𝗰𝗲𝗿 𝗧𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝗣𝗶𝗽𝗲𝗹𝗶𝗻𝗲 𝘄𝗶𝘁𝗵 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝘃𝗲 𝗔𝗻𝘁𝗶𝗯𝗼𝗱𝘆-𝗗𝗿𝘂𝗴 𝗖𝗼𝗻𝗷𝘂𝗴𝗮𝘁𝗲𝘀 𝗧𝗵𝗲𝗿𝗮𝗽𝘆 𝗜𝗻𝘃𝗲𝘀𝘁𝗺𝗲𝗻𝘁! 𝗜𝗻 𝗙𝗲𝗯𝗿𝘂𝗮𝗿𝘆 𝟮𝟬𝟮𝟰, 🕬 Pfizer is turning to focus on #cancer , with a laser focus on next-generation #antibodydrugconjugates (ADCs), small #molecules💊, and bispecific antibodies, following significant investments in #covid19 -19 🞿 during the past few years. Pfizer now has 60 cancer initiatives, quadruple its previous level. Pfizer has 🚨 refocused its efforts on four primary cancer categories: hematology-oncology, which includes multiple #myeloma💉and #lymphomas; genitourinary cancer, which includes prostate and urothelial cancers; and #thoracic cancers, including #lung, #head, and #neck cancers. Using three different modalities—small compounds, ADCs, and bispecific antibodies—as well as additional immuno-oncology biologics💉💅, the pharma giant is currently investigating 🔬 the four main areas. With the use of Seagen's ADC technology and Pfizer's protein engineering and 🟂antibody design skills, the company's next-generation ADC platform allows it to target new targets🖸 and create better, more distinctive payloads. 𝗕𝗿𝗼𝘄𝘀𝗲 𝗮𝘁 𝗼𝘂𝗿 𝗟𝗶𝗻𝗸𝗲𝗱 𝗥𝗲𝗽𝗼𝗿𝘁 👉: https://bit.ly/3UZP4Wg #pfizer   #oncology #multiplemyeloma  #rarediseases #genetherapy #proteinengineering #prophecymarketinsights

Close to 200 Liquid biopsy trials in oncology are registered between 2021-2022. This area is growing by leaps and bounds. From disease monitoring to therapy guidance liquid biopsy is the future of cancer treatment. Importantly, a cancer drug which is developed in parallel with a CDx assay (companion diagnostic or liquid biopsy assay in this context) can reduce drug development cost by 60%- not to mention that cancer drug development cost could be as high as >$1B. Therefore, liquid biopsy has huge impact on cost reduction in drug development process. Surprisingly, data shows that a new cancer drug application filed to FDA see as high as 30% approval rate as oppose to 8-10% when without CDx assay. The impact of liquid biopsy technologies in patient care as well as in drug development process is far from realized yet and could make a tectonic shift in oncology research in coming years. #oncology #pharma #liquidbiopsy #cancer #immunooncology #biotech https://lnkd.in/dKf-h4ac.

𝐔𝐧𝐫𝐚𝐯𝐞𝐥𝐥𝐢𝐧𝐠 𝐭𝐡𝐞 𝐂𝐨𝐦𝐩𝐥𝐞𝐱𝐢𝐭𝐲 𝐨𝐟 𝐭𝐡𝐞 𝐋𝐮𝐧𝐠 𝐂𝐚𝐧𝐜𝐞𝐫 𝐀𝐃𝐂 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜 𝐋𝐚𝐧𝐝𝐬𝐜𝐚𝐩𝐞 The therapeutic landscape for lung cancer is undergoing a transformative phase with the development of Antibody-Drug Conjugates (ADCs). This innovative class of therapeutics combines the specificity of antibodies with the potency of cytotoxic drugs, aiming to deliver targeted treatments to cancer cells while minimizing damage to healthy tissue. The intricacies of this landscape are elegantly captured in the latest TheraTrack infographic. This visualization maps out the progression of numerous ADCs from preclinical stages through to full approval. The graphic delineates the dynamic and competitive environment, highlighting multiple drug targets such as EGFR, HER2, and TROP-2, and showcases the players involved at each phase of development. As we track the journey of these drugs, it's clear that the landscape is not only rich with potential but also with the complexity of clinical focus. The transition from preclinical curiosity to approved treatment is a testament to the relentless pursuit of innovation in oncology. This detailed analysis serves as a beacon for investors, researchers, and healthcare professionals, guiding strategic decisions and fostering collaborations that will shape the future of lung cancer treatment. [Data visualized and presented by DeciBio] #Oncology #LungCancer #ADC #Biotech #Pharma #ClinicalDevelopment #Innovation

#AntiBodyConjugates (#ADC) trials by phase and #Tumor type

The #LungCancer space has never been busier (IMHO). 📛 From a priority review pathway, the US FDA approves Amgen's tarlatamab/Imdelltra, for use in advanced small cell lung cancer (SCLC), which pluses up ➕ its bispecific T-cell engagers (BiTE). So, what are BiTEs? I like Phil Taylor/pharmaphorum's description: 🔬 "BiTE drugs are designed to engage the immune system against cancer by bringing T-cells and cancer cells into close proximity. In the case of tarlatamab, the molecule binds to CD3 receptors on T-cells and DLL3 on SCLC cells, and it is the first drug in the anti-DLL3 class to be approved for marketing, as well as the first BiTE for a solid tumour." re: the DLL3's: ♣ Other programs in play, namely, from Boehringer Ingelheim (having a fast-tracked asset) and Harpoon Therapeutics (a tri-specific; in prostate cancer studies) Is Lung Cancer or these innovative MOAs/targets an area of particular interest? Contact your team of Life Science Associates at Fletcher to learn more about our solutions, capabilities, and strength of our in-depth studies to support and inform on your strategic priorities! #LungCancer #Oncology #SolidTumor #Innovation #Regulatory #Pharma #Healthcare